Shopping Cart 0
Cart Subtotal
USD 0

Female Sexual Dysfunction-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Female Sexual Dysfunction-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction-Pipeline Review, H2 2017, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 8, 5 and 3 respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).

The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Sexual Dysfunction-Overview

Female Sexual Dysfunction-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Female Sexual Dysfunction-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Sexual Dysfunction-Companies Involved in Therapeutics Development

Allergan Plc

Callitas Therapeutics Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

GlaxoSmithKline Plc

M et P Pharma AG

Palatin Technologies Inc

Pivot Pharmaceuticals Inc

Re-Pharm Ltd

S1 Biopharma Inc

Strategic Science & Technologies LLC

TherapeuticsMD Inc

Female Sexual Dysfunction-Drug Profiles

(buspirone hydrochloride + testosterone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(sildenafil citrate + testosterone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

estradiol acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FKW-00GA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepirone hydrochloride ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasterone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVT-011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S1B-3006-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S1B-307-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIP-104-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Sexual Dysfunction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Estrogen Receptor for Female Sexual Dysfunction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBS-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WC-3011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Sexual Dysfunction-Dormant Projects

Female Sexual Dysfunction-Discontinued Products

Female Sexual Dysfunction-Product Development Milestones

Featured News & Press Releases

Dec 19, 2017: TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act Date for TX-004HR

Nov 29, 2017: TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR

Nov 06, 2017: TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR

Nov 03, 2017: TherapeuticsMD Provides Update on TX-004HR

Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission

Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-004HR at NAMS

Sep 14, 2017: TherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR

Aug 10, 2017: TherapeuticsMD Provides Regulatory Update On TX-004HR

Jul 24, 2017: AMAG Pharmaceuticals Launches Intrarosa (prasterone) in the U.S.-a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause

Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA

Jul 17, 2017: TherapeuticsMD Provides Update on TX-004HR

Jul 14, 2017: M Pharmaceutical Provides Update on Extrinsa

Jun 06, 2017: M Pharmaceutical Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction

May 08, 2017: TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application

May 02, 2017: TherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Female Sexual Dysfunction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Female Sexual Dysfunction, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Female Sexual Dysfunction-Pipeline by Allergan Plc, H2 2017

Female Sexual Dysfunction-Pipeline by Callitas Therapeutics Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Emotional Brain BV, H2 2017

Female Sexual Dysfunction-Pipeline by EndoCeutics Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017

Female Sexual Dysfunction-Pipeline by GlaxoSmithKline Plc, H2 2017

Female Sexual Dysfunction-Pipeline by M et P Pharma AG, H2 2017

Female Sexual Dysfunction-Pipeline by Palatin Technologies Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Pivot Pharmaceuticals Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Re-Pharm Ltd, H2 2017

Female Sexual Dysfunction-Pipeline by S1 Biopharma Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Strategic Science & Technologies LLC, H2 2017

Female Sexual Dysfunction-Pipeline by TherapeuticsMD Inc, H2 2017

Female Sexual Dysfunction-Dormant Projects, H2 2017

Female Sexual Dysfunction-Dormant Projects, H2 2017 (Contd..1), H2 2017

Female Sexual Dysfunction-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Allergan Plc

Callitas Therapeutics Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

GlaxoSmithKline Plc

M et P Pharma AG

Palatin Technologies Inc

Pivot Pharmaceuticals Inc

Re-Pharm Ltd

S1 Biopharma Inc

Strategic Science & Technologies LLC

TherapeuticsMD Inc

Female Sexual Dysfunction-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction-Pipeline Review, H2 2017, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 8, 5 and 3 respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).

The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Sexual Dysfunction-Overview

Female Sexual Dysfunction-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Female Sexual Dysfunction-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Sexual Dysfunction-Companies Involved in Therapeutics Development

Allergan Plc

Callitas Therapeutics Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

GlaxoSmithKline Plc

M et P Pharma AG

Palatin Technologies Inc

Pivot Pharmaceuticals Inc

Re-Pharm Ltd

S1 Biopharma Inc

Strategic Science & Technologies LLC

TherapeuticsMD Inc

Female Sexual Dysfunction-Drug Profiles

(buspirone hydrochloride + testosterone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(sildenafil citrate + testosterone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

estradiol acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FKW-00GA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepirone hydrochloride ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasterone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVT-011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S1B-3006-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S1B-307-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIP-104-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Sexual Dysfunction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Estrogen Receptor for Female Sexual Dysfunction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBS-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WC-3011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Sexual Dysfunction-Dormant Projects

Female Sexual Dysfunction-Discontinued Products

Female Sexual Dysfunction-Product Development Milestones

Featured News & Press Releases

Dec 19, 2017: TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act Date for TX-004HR

Nov 29, 2017: TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR

Nov 06, 2017: TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR

Nov 03, 2017: TherapeuticsMD Provides Update on TX-004HR

Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission

Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-004HR at NAMS

Sep 14, 2017: TherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR

Aug 10, 2017: TherapeuticsMD Provides Regulatory Update On TX-004HR

Jul 24, 2017: AMAG Pharmaceuticals Launches Intrarosa (prasterone) in the U.S.-a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause

Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA

Jul 17, 2017: TherapeuticsMD Provides Update on TX-004HR

Jul 14, 2017: M Pharmaceutical Provides Update on Extrinsa

Jun 06, 2017: M Pharmaceutical Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction

May 08, 2017: TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application

May 02, 2017: TherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Female Sexual Dysfunction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Female Sexual Dysfunction, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Female Sexual Dysfunction-Pipeline by Allergan Plc, H2 2017

Female Sexual Dysfunction-Pipeline by Callitas Therapeutics Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Emotional Brain BV, H2 2017

Female Sexual Dysfunction-Pipeline by EndoCeutics Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017

Female Sexual Dysfunction-Pipeline by GlaxoSmithKline Plc, H2 2017

Female Sexual Dysfunction-Pipeline by M et P Pharma AG, H2 2017

Female Sexual Dysfunction-Pipeline by Palatin Technologies Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Pivot Pharmaceuticals Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Re-Pharm Ltd, H2 2017

Female Sexual Dysfunction-Pipeline by S1 Biopharma Inc, H2 2017

Female Sexual Dysfunction-Pipeline by Strategic Science & Technologies LLC, H2 2017

Female Sexual Dysfunction-Pipeline by TherapeuticsMD Inc, H2 2017

Female Sexual Dysfunction-Dormant Projects, H2 2017

Female Sexual Dysfunction-Dormant Projects, H2 2017 (Contd..1), H2 2017

Female Sexual Dysfunction-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Allergan Plc

Callitas Therapeutics Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

GlaxoSmithKline Plc

M et P Pharma AG

Palatin Technologies Inc

Pivot Pharmaceuticals Inc

Re-Pharm Ltd

S1 Biopharma Inc

Strategic Science & Technologies LLC

TherapeuticsMD Inc